Approved For Marketing EXPANDED_ACCESS NCT00520143

Alglucosidase Alfa Temporary Access Program (ATAP)

Sponsor: Genzyme, a Sanofi Company

Conditions Acid Maltase Deficiency Disease Glycogen Storage Disease Type II (GSD-II) Glycogenosis 2 Pompe Disease (Late-Onset)

Interventions alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])

Updated 8 times since 2017 Last updated: Feb 4, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Acid Maltase Deficiency Disease and Glycogen Storage Disease Type II (GSD-II) and is currently ongoing. Genzyme, a Sanofi Company leads this study, which shows 8 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Approved For Marketing
Sep 2024 — Sep 2025 [monthly]

Approved For Marketing
Jul 2024 — Sep 2024 [monthly]

Approved For Marketing
Jan 2021 — Jul 2024 [monthly]

Approved For Marketing
Jun 2018 — Jan 2021 [monthly]

Approved For Marketing

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Approved For Marketing

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Approved For Marketing NA
Jan 2017 — Feb 2017 [monthly]

Approved For Marketing NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Anchorage, United States , Asheville, United States , Augusta, United States , Aurora, United States , Bakersfield, United States , Baltimore, United States , Beverly Hills, United States , Boise, United States and 63 more locations